BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36427644)

  • 1. Radiation Therapy Expenditures Through the First 8 Performance Periods of the Oncology Care Model at a Statewide Multispecialty Health System.
    De B; Andres G; Bates C; Staren E; Kutscher E; Brooks DJ; Thaker GH; Buscema J; Gin R; Thaker N
    Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):491-499. PubMed ID: 36427644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drivers of Medicare Spending: A 15-Year Review of Radiation Oncology Charges Allowed by the Medicare Physician/Supplier Fee-for-Service Program Compared With Other Specialties.
    Mokhtech M; Laird JH; Maroongroge S; Zhu D; Falit B; Johnstone PAS; Mantz CA; Ennis RD; Sandler HM; Dosoretz AP; Yu JB
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):322-327. PubMed ID: 33412264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
    Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
    JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model.
    Baumgardner JR; Shahabi A; Linthicum MT; Zacker C; Lakdawalla DN
    J Oncol Pract; 2018 Nov; 14(11):e699-e710. PubMed ID: 30423271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes.
    Baumgardner J; Shahabi A; Linthicum M; Vine S; Zacker C; Lakdawalla D
    J Manag Care Spec Pharm; 2018 Jun; 24(6):504-513. PubMed ID: 29799330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of characteristics associated with higher-value radiotherapy episodes of care for bone metastases in Medicare fee-for-service beneficiaries.
    Marshall D; Aldridge MD; Dharmarajan K
    BMJ Open; 2021 Oct; 11(10):e049009. PubMed ID: 34667003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmarking the Radiation Oncology Alternative Payment Model: Changes in Medicare Reimbursement for 16 Common Radiation Therapy Treatment Courses.
    Hogan JS; Karraker P; Fischer-Valuck BW; Vapiwala N; Mehta MP; Perez CA; Baumann JC; Bradley JD; Baumann BC
    Pract Radiat Oncol; 2023; 13(5):e389-e394. PubMed ID: 37172757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?
    Rocque GB; Williams CP; Kenzik KM; Jackson BE; Halilova KI; Sullivan MM; Rocconi RP; Azuero A; Kvale EA; Huh WK; Partridge EE; Pisu M
    J Oncol Pract; 2018 Jun; 14(6):e375-e383. PubMed ID: 28981388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
    Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
    BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Myeloma Cost of Care Under the Oncology Care Model: The Influence of High-Cost Therapies.
    Theroux H; Williams A; Liu M; Dahl A; Dreyer T; Horvath K; Isola L
    JCO Oncol Pract; 2020 Oct; 16(10):e1078-e1084. PubMed ID: 32459566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Patient Stage and Disease Characteristics on the proposed Radiation Oncology Alternative Payment Model (RO-APM).
    Waddle MR; Stross WC; Vallow LA; Naessens JM; White L; Meier S; Spaulding AC; Buskirk SJ; Trifiletti DM; Keole SR; Ma DJ; Bajaj GK; Laack NN; Miller RC
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):905-911. PubMed ID: 32001382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the Oncology Care Model With Value-Based Changes in Use of Radiation Therapy.
    Kapadia NS; Brooks GA; Landrum MB; Riedel L; Liu PH; Hassol A; Tripp AS; Jhatakia S; Kummet CM; Keating NL
    Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):39-46. PubMed ID: 35150787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Utilization and Medicare Spending on Short-Course Radiation Therapy for Breast and Prostate Cancer: An Episode-Based Analysis From 2015 to 2019.
    Patel TA; Jain B; Vapiwala N; Chino F; Tringale KR; Mahal BA; Yamoah K; McBride SN; Lam MB; Hubbard A; Nguyen PL; Dee EC
    Int J Radiat Oncol Biol Phys; 2024 May; 119(1):17-22. PubMed ID: 38072324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource utilization, quality metrics, and costs of bladder cancer within the Oncology Care Model.
    Wirtz HS; Hepp Z; Grewal S; Wright P; Fuldeore R; Tomicki S; Hirsch J; Dieguez G; Blakely LJ
    Am J Manag Care; 2023 May; 29(5):e136-e142. PubMed ID: 37229787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated Big Data Analytics for the Radiation Oncology Alternative Payment Model Proposal Using a Novel Health Care Software Technology.
    Thaker NG; Holloway J; Hodapp C; Mellen M; Fryefield D; Meghani R; Tong K; Rose CM
    JCO Oncol Pract; 2020 Apr; 16(4):e333-e340. PubMed ID: 32155108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
    Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
    J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Radiation Oncology Alternative Payment Model on Community Cancer Centers.
    Meeks SL; Mathews R; Mojica J; Shah AP; Kelly P; Dvorak T
    JCO Oncol Pract; 2021 Dec; 17(12):e1949-e1957. PubMed ID: 34460290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in and Factors Contributing to the Slowdown in Medicare Spending Growth, 2007-2018.
    Buntin MB; Freed SS; Lai P; Lou K; Keohane LM
    JAMA Health Forum; 2022 Dec; 3(12):e224475. PubMed ID: 36459161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
    San-Juan-Rodriguez A; Gellad WF; Shrank WH; Good CB; Hernandez I
    J Manag Care Spec Pharm; 2021 May; 27(5):565-573. PubMed ID: 33908276
    [No Abstract]   [Full Text] [Related]  

  • 20. Geographic Variation in Medicare Fee-for-Service Health Care Expenditures Before and After the Passage of the Affordable Care Act.
    Sood N; Yang Z; Huckfeldt P; Escarce J; Popescu I; Nuckols T
    JAMA Health Forum; 2021 Dec; 2(12):e214122. PubMed ID: 35977300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.